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ABSTRACT 1 
Lung function decline is a well-recognized complication following allogeneic stem cell 2 
transplantation (allo-SCT). Reduced-intensity conditioning (RIC) and in vivo T-cell depletion 3 
by administration of antithymocyte globulin (ATG) may play a protective role in the 4 
occurrence of late pulmonary complications. This retrospective study reported the evolution 5 
of lung function parameters within the first 2 years after allo-SCT, in a population receiving 6 
the same RIC regimen including fludarabine and i.v. busulfan in combination with low dose 7 
ATG. The median follow-up was 35.2 months. With a median age of 59 years at time of 8 
transplant, at 2 years, the cumulative incidences of non-relapse mortality was as low as 9.7%. 9 
The cumulative incidence of relapse was 33%. At 2 years, the cumulative incidences of 10 
extensive chronic graft-versus-host disease (cGVHD) and of pulmonary cGVHD were 23.1% 11 
and 1.9%, respectively. The cumulative incidences of airflow obstruction and restrictive 12 
pattern were 3.8% and 9.6%, respectively. Moreover, FEV1, FVC and FEV1/FVC ratio 13 
remained stable from baseline up to 2 years post transplantation (p=0.26, p=0.27 and p=0.07, 14 
respectively). These results compare favorably with results obtained with other RIC regimens 15 
not incorporating ATG, and suggest that ATG may play a protective pulmonary role after 16 
allo-SCT. 17 
Key Words: pulmonary function, reduced intensity conditioning, ATG 18 
 19 
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INTRODUCTION 1 
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a well-established therapy 2 
for several hematological diseases. Unfortunately, allo-SCT is limited by the high incidence 3 
of non-relapse mortality (NRM), mainly due to acute and chronic graft versus host disease 4 
(aGVHD, cGVHD) 1. Importantly, pulmonary complications, which occur in 30 to 60% of 5 
patients after allo-SCT 2, account for meaningful mortality and morbidity, and up to 50% of 6 
transplant-related deaths.3 Multiple factors can contribute to pulmonary complications, 7 
notably the type of conditioning regimen used. Reduced-intensity conditioning (RIC) 8 
regimens are being used with the aim of decreasing NRM in elderly patients, in heavily 9 
pretreated patients or in patients with medical comorbidities precluding the use of standard 10 
myeloablative conditioning (MAC). One study already showed that the use of RIC regimen 11 
can reduce the risk of developing late pulmonary complications, with protection against 12 
declining lung function and a reduced incidence of bronchiolitis obliterans syndrome (BOS) 4. 13 
Beyond the degree of myeloablation of the preparative regimen itself (RIC or standard 14 
myeloablative conditioning), it is well admitted that the use of total body irradiation (TBI) in 15 
the conditioning is also associated with pulmonary toxicity 5. In contrast, in vivo T cell 16 
depletion seems to reduce the risk of developing pulmonary complications after allo-SCT 6. 17 
Also, cGHVD has been identified as a risk factor for late onset non-infectious pulmonary 18 
complications and in particular BOS 7-10. On the other hand, cGVHD is usually significantly 19 
reduced in patients receiving in vivo T cell depletion by administration of antithymocyte 20 
globulins (ATG) 11. However, the onset of long term pulmonary complication in patients 21 
receiving an ATG-based RIC regimen, without TBI, has not yet been investigated. This study 22 
evaluated the evolution of lung function parameters within the first 2 years following allo-23 
SCT, in a population undergoing the same RIC regimen including fludarabine, i.v. busulfan in 24 
combination with low dose ATG. 25 
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PATIENTS AND METHODS 1 
Patients’ characteristics 2 
This retrospective single-center study included 52 consecutive patients who received allo-3 
SCT between January 2007 and September 2010 at the University Hospital of Nantes (CHU 4 
de Nantes, Nantes, France). Per study inclusion criteria, all patients with available pre- and 5 
post-transplant pulmonary function tests (PFT) and who received RIC regimen including 30 6 
mg/m2 fludarabine for 5 or 4 consecutive days, 6.4 mg/kg total dose IV busulfan and 5 mg/kg 7 
total dose ATG (Thymoglobulin; Genzyme/Sanofi, Lyon, France), were included. In our 8 
transplant program, eligibility criteria for RIC allo-SCT that preclude the use of standard 9 
myeloablative conditioning (MAC) allo-SCT include: (i) patient age older than 50 years; (ii) 10 
heavily pretreated patients who received auto-SCT or with more than 2 lines of chemotherapy 11 
before allo-SCT; and (iii) patients with poor performance status because of significant 12 
medical comorbidities as described by Sorror et al 12. Patients were treated as part of different 13 
prospective clinical trials, and written informed consent was obtained from each patient and 14 
donor. All clinical data were prospectively collected. 15 
All patients received the preparative regimen as inpatients in private rooms, and remained 16 
hospitalized until hematopoietic and clinical recovery. 29 donors (56%) were HLA-identical 17 
sibling donors, while 20 (38%) were HLA-unrelated donors (MUD) and 3 (6%) were HLA 18 
unrelated donors with one locus mismatch. The stem cell source was bone marrow in 2 cases 19 
(4%) and G-CSF-mobilized peripheral blood stem cells in 50 cases (96%). In this series, the 20 
median age was 59 (range, 23-70) years. Twenty-two patients were treated for acute myeloid 21 
leukemia (42%), 10 patients had a myelodysplastic syndrome (19%), 13 patients had non 22 
Hodgkin lymphoma (25%), 3 patients had Hodgkin disease (6%), 3 patients had multiple 23 
myeloma (6%) and 1 patient had acute lymphoblastic leukemia (2%). 24 
Supportive care and antimicrobial prophylaxis were given as reported previously 13. For 25 
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GVHD prophylaxis, patients received either CSA alone in case of an HLA-sibling donor or 1 
CSA and mycophenolate mofetil (MMF) in case of an HLA-matched unrelated donor 14. In 2 
this series, CSA was administered at a dose of 3 mg/kg/day by continuous intravenous 3 
infusion starting from day -3 or -2, and changed to twice daily oral dosing as soon as tolerated 4 
15. MMF was given at a fixed oral dose of 2 g/day. No treatment adjustment was performed 5 
for MMF. MMF was decreased progressively over 4 weeks starting from day 60 and CSA 6 
from day 90 if no GVHD appeared. Of note, during the whole study period supportive care 7 
was the same. CMV infection management was also homogeneous. All blood products were 8 
filtered irradiated and CMV screened. In the first 100 days post allo-SCT, patients were 9 
assessed at least once per week for CMV reactivation by PCR assay in order to initiate 10 
preemptive ganciclovir therapy. Acute GVHD was evaluated according to the Seattle standard 11 
criteria 16. 12 
 13 
Pulmonary Function Testing 14 
PFT were performed before allo-SCT and then repeated 100 days, one and two years after 15 
transplant. All PFT were performed in the same laboratory in accordance with the American 16 
Thoracic Society and European Respiratory Society criteria 17. Lung volumes and spirometry 17 
were measured with a Jaeger constant volume body plethysmograph with a 18 
pneumotachograph connected to an Epson PC-AT (Epson, Suwa, Japan). All PFT values, 19 
except FEV1/FVC ratio were expressed as a percentage of predicted values in healthy controls 20 
with corresponding age and gender. Published equations were used to calculate predicted 21 
values of forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), total 22 
lung capacity (TLC) and lung carbon monoxide diffusing capacity (DLCO) 18. DLCO was 23 
measured using the single breath technique of Ogilvie et al. and corrected for the most recent 24 
hemoglobin concentration but not corrected for the alveolar volume 19. In those patients who 25 
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received a bronchodilator challenge, the prebronchodilator values were used. A lung function 1 
score (LuFS) was calculated before transplantation, and at day 100, 1 year and 2 years after 2 
transplant in order to grade the extent of lung function impairment (if any). A separate score 3 
was assigned to relative values of FEV1 and DLCO (>80% = 1, 70-79% = 2, 60-69% = 3, 50-4 
59% = 4, 40-49%=5, <40%=6), these scores were then summed and divided into four 5 
categories as LuFS (LuFS score 2 = category 0 [normal]; LuFS score 3-5 = category 1 [mildly 6 
decreased]; LuFS score 6-9 = category 2 [moderately decreased]; LuFS score 10-12 = 7 
category 3 [severely abnormal]), according to NIH recommendations 20. Restrictive lung 8 
disease (RLD) was defined as TLC <80% of the predicted value, and was graded as mild at 9 
70–79%, moderate at 60–69%, moderately severe at 50–59%, and severe at <50%. Diffusion 10 
impairment was defined as DLCO <80% of the predicted value and was graded as mild at 60–11 
79%, moderate at 40–59%, and severe at <40% 21. Airflow obstruction (AFO) was defined by 12 
a FEV1/FVC < 70. Criteria from the NIH consensus guidelines were used for diagnosis of 13 
BOS: 1) FEV1/ FVC < 70% and FEV1 < 75% of predicted value, 2) radiological, histological 14 
or lung volume evidence of air trapping and 3) absence of respiratory tract infection 20. 15 
The occurrence of infectious respiratory complications during the follow-up period of interest 16 
was collected in medical records. Expiration scans to evaluate air trapping, chest high 17 
resolution computed tomography and bronchoalveolar lavage with bacterial, fungal and 18 
virological searches were left to the discretion of the attending physician, according to 19 
symptoms presented by the patient. 20 
 21 
Statistical Methods 22 Continuous	   variables	   were	   presented	   as	   mean	   ±	   standard	   deviation	   (SD)	   or	   median	  23 (range),	   categorical	   variables	  as	   count	  and	  percent.	  Mixed models were used to analyze 24 
PFT data during time (before transplantation until 2 years post transplantation). Comparison 25 
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between LuFS scores before transplantation and at 100 days, 1 year and 2 years post 1 
transplantation was performed with the McNemar's test. Overall survival (OS) and 2 
progression-free survival (PFS) were calculated by the Kaplan-Meier method. Probabilities of 3 
relapse, NRM and GVHD were calculated using the cumulative incidence procedure. The risk 4 
of respiratory failure, RP and AFO were also calculated using the cumulative incidence 5 
procedure with death considered as the competing event. Data were computed using SAS	  6 software	  version	  9. 3,	  the	  R package (R Development Core Team, 2006. R: A language and 7 
environment for statistical computing. R Foundation for Statistical Computing, Vienna, 8 
Austria. ISBN 3-900051-07-0, URL http://www.R-project.org) and GraphPad Prism 5.0 9 
(GraphPad Software, San Diego, CA). 10 
 11 
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RESULTS 1 
Patients’ characteristics 2 
In this series, the overall median follow-up was 35.2 months (range, 20.0-59.8) among 3 
surviving patients. Patients, donors and transplant characteristics are summarized in Table 1. 4 
The median age was 59 (range 23-70) years. Patients engrafted at a median of 17 (range, 0-5 
48) days after allo-SCT. The cumulative incidence of severe grade III-IV aGVHD at day 100 6 
was 15.4%. At 2 years, the cumulative incidence of extensive cGVHD was 23.1%. In this 7 
series, 23 (44%) patients were active or former smokers while 21 (40%) never smoked. 8 
Smoker status data were missing for 8 patients (15%). 9 
 10 
PFT and development of airflow obstruction and restrictive pattern 11 
Pretransplantation PFT were performed at a median of 17 (range, 10-76) days before allo-12 
SCT. Subsequently, PFT were performed at a median of 101 (range, 77-119), 365 (range, 13 
251-490) and 717 (range, 588-846) days after transplantation. The proportion of surviving 14 
patients with available PFT was 85%, 89% and 82% at day 100, 1 year and 2 years, 15 
respectively. PFT data before transplantation and at day 100, 1 year and 2 years 16 
postransplantation are summarized in Table 2. Before stem cell transplantation, lung function 17 
was normal in 83% (n=43) of patients, while 6 patients met the criteria for obstructive lung 18 
disease defined as FEV1/FVC <70, and 3 patients had restrictive lung disease, defined as 19 
TLC <80%. Restrictive lung disease was graded as mild for 2 patients and moderate for one. 20 
Among patients with a pretransplantation obstructive pattern, only one patient had a FEV1 21 
inferior to 75% predicted. DLCO was impaired (mean value <80%) in 83% of patients before 22 
transplantation, and remained altered but stable from baseline up to 2 years post 23 
transplantation (p=0.84). Furthermore, 60% (n=31) had a mild diffusion impairment, 19% 24 
(n=10) a moderate diffusion impairment, and 4% (n=2) a severe diffusion impairment of 25 
DLCO (Figure 1 E). FEV1, FEV1/FVC ratio, FVC and TLC remained stable from baseline 26 
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up to 2 years post transplantation (p= 0.26, p=0.07, p=0.27, p=0.44, respectively) (Figure 1 1 
A-D). Evaluation of LuFS showed a mildly abnormal lung function (category 1) in 44 patients 2 
(77%) at baseline. From baseline up to 2 years, LuFS score remained stable with most of 3 
patients with normal or mildly abnormal lung function, and no patient had a severely 4 
abnormal lung function (Figure 2). There was no statistical difference when comparing time-5 
points: before allo-SCT versus 100 days (p=0.53), before allo-SCT vs 1 year (p=0.29), and 6 
before allo-SCT versus 2 years (p=0.54). 7 
 8 
Mortality, infectious and non-infectious pulmonary complications  9 
Of the 52 patients included in this study, a total of 19 patients died (36.5%) during the follow-10 
up period. Overall survival, cumulative incidences of relapse and NRM rates at 2 years after 11 
allo-SCT were 65% (95% CI, 51-76%), 33% and 9.7% respectively. Four deaths (21%) were 12 
related to GVHD, 1 (5%) death was directly related to a pulmonary cause (pleuro-13 
pericarditis), and 1 (5%) due to a secondary malignancy. The remaining 13 (69%) deaths were 14 
caused by relapse or progression of original disease. In this series, 8 patients presented a 15 
possible or probable invasive aspergillosis before transplantation (1 to 8 months before). After 16 
transplantation, two patients presented a possible aspergillosis (3 months and one year after 17 
transplantation) and one patient presented a probable aspergillosis 4 months after allo-SCT 22. 18 
None of the patients was diagnosed with a CMV disease within 2 years after transplantation. 19 
At 2 years, the cumulative incidence of AFO and RP was 3.8% and 9.6% respectively. RP 20 
was graded as mild for the majority of patients. The cumulative incidence of pulmonary 21 
cGVHD at 2 years was 1.9%, and only one patient met the criteria for BOS diagnosis 22 
according to the NIH consensus guidelines 20 during the follow-up period of interest. 23 
 24 
  25 
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DISCUSSION 1 
In this study, we reported a stable pulmonary function with a low rate of pulmonary 2 
complications including airflow obstruction, restrictive lung disease and BOS in the two years 3 
following allo-SCT conditioned by fludarabine, i.v. busulfan and ATG. It is well established 4 
that pulmonary complications are a major cause of morbidity and mortality after allo-SCT and 5 
occur in 30 to 60% of cases, and up to 80% in autopsy studies 2, 23. Infectious complications 6 
are the more frequent, especially in the early phase after allo-SCT, however, many non-7 
infectious pulmonary complications can occur after allo-SCT: restrictive lung disease, 8 
impaired gas exchange or obstructive lung disease in particular in patients with concomitant 9 
cGVHD 21.  10 
The advent of RIC regimen allowed to perform allo-SCT in older patients or young patients 11 
with severe comorbidities, including pulmonary comorbidities. The type of agents used as 12 
part of the RIC regimens is a crucial determinant for the occurrence of pulmonary 13 
complications. In the current study, we analyzed the results of a well-established RIC regimen 14 
combining fludarabine, intermediate dose of i.v. busulfan and ATG (Thymoglobulin®) used 15 
at a total dose of 5 mg/Kg. Such regimen combines an effective disease control with low 16 
NRM and an acceptable toxicity profile 24-26. In our study, RP and AFO cumulative 17 
incidences remained very low, at 3.8% and 9.6% respectively, suggesting that such regimen 18 
does not induce a significant pulmonary toxicity. Indeed, fludarabine is known to be less toxic 19 
to the pulmonary system than the traditional cyclophosphamide 27. On the other hand, high 20 
dose busulfan, along with cGVHD are the main risk factors identified for spirometric 21 
obstruction 21, 28-30. Furthermore, low dose TBI which is another component of RIC protocols, 22 
remains an important risk factor of airflow decline, despite changes in TBI techniques aiming 23 
to limit pulmonary toxicity 31. Regarding ATG, previous data from the standard 24 
myeloablative setting already suggested a potential protective role of this agent on lung 25 
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function. The GITMO randomized trials 32 showed that in patients receiving ATG, FEV1 and 1 
FVC values remained stable at 2 years after allo-SCT (ΔFEV1, -3% and ΔFVC, +3%), 2 
whereas there was a significant decrease of FEV1 and FVC and an increase of cGVHD in the 3 
non-ATG group. Our results in the RIC setting are in accordance with these findings, further 4 
supporting the value of ATG towards reducing the incidence and severity of GVHD 33. Here, 5 
we reported a low cumulative incidence of extensive cGVHD at 2 years (23.1%). Such 6 
protective role of ATG on lung function is likely mediated (at least in part) by its 7 
effectiveness in reducing overall cGVHD. Indeed, pulmonary damage occurs during cGVHD, 8 
and BOS is well linked to cGVHD. According to previous studies, BOS incidence ranges 9 
from 6 to 20% in long term survivors 34. This important variability is probably related to 10 
many parameters, including the nature of conditioning regimen, stem cell source, type of 11 
donor etc. Furthermore, different definitions of airflow obstruction have been used over the 12 
years to define BOS, contributing to this variability. We chose to apply the most recent NIH 13 
criteria 20, and reported results according to the cumulative incidence procedure which is more 14 
appropriate. In our cohort, despite the use of busulfan, the cumulative incidence of BOS was 15 
very low (1.9%), supporting a protective role of ATG in the occurrence of cGVHD and BOS. 16 
In addition, cGVHD might be responsible for indirect lung damage: severe chronic 17 
scleroderma GVHD can lead to true RP. Thus, one may reasonably conclude that ATG can 18 
contribute to the low cumulative incidence of RP (9.6%) observed in our study. One classical 19 
argument against the use of ATG is the higher risk of opportunistic infections and disease 20 
relapse. However, in our study, the use of ATG did not result in an increased incidence of 21 
relapse, in contrast to the study by Soiffer et al 35. This difference may be explained by the 22 
lower dose of ATG we used (5 mg/Kg total dose). Likewise, whereas higher doses of ATG 23 
are known to favor infections, there were very few infectious pulmonary complications in our 24 
cohort, in line with our previously published findings36. Furthermore, low cumulative 25 
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incidence of extensive cGVHD and NRM at 2 years (23.1% and 9.7% respectively), compare 1 
favorably with long term follow-up of the German randomized ATG study37: at 3 years, the 2 
cumulative incidence of extensive cGVHD and NRM were 12.2% and 19.4% respectively in 3 
the ATG group and 45.0% and 33.5% respectively in the non ATG group. Thus ATG seems 4 
to exert a strong protective effect against severe cGVHD, leading to a low NRM incidence, 5 
indicating a good quality of life, since extensive cGVHD is well known to be responsible for 6 
a worsened quality of life38. 7 
In the current series, a significant percentage of patients had DLCO impairment before allo-8 
SCT. After allo-SCT, DLCO remained impaired, but without evidence of worsening, as 9 
previously described in the paediatric setting 39. The baseline impairment of DLCO in these 10 
patients is likely multifactorial reflecting previous bacterial and viral infections, or toxicities 11 
related to prior chemotherapy.40. The impact of baseline DLCO impairment on outcome is 12 
still controversial. However, a few studies have suggested a significant impact of DLCO 13 
values on transplant outcome 41, 42 43. 14 
Unfortunately, in the current study, we were not able to compare the results obtained using 15 
the fludarabine, i.v. busulfan and ATG-based RIC regimen with a similar regimen not 16 
containing ATG, because this is not common practice in our centre. Likewise, one may argue 17 
that lung function measurements performed during the first 2 years after allo-SCT may not be 18 
sufficient as lung function decline could appear after 2 years, and up to 18 years after allo-19 
SCT 1, 21, 28, 44. However, one must acknowledge that reduction in lung volumes and diffusing 20 
capacity often occurred early within 12 months after allo-SCT, followed by an incomplete 21 
recovery within the next two years 21, 45. 22 
In conclusion, we report a low rate of pulmonary complications and lung function impairment 23 
in patients undergoing a RIC regimen including fludarabine, i.v. busulfan and low dose of 24 
ATG. These results further support the use of ATG as part of the so-called reduced-toxicity 25 
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regimens aiming to decrease long-term toxicities and to improve patients’ quality of life. 1 
2 
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FIGURE LEGENDS 1 
Figure 1. Changes in PFT parameters from baseline up to 2years post allo-SCT. Data are 2 
represented by boxplot. FEV1, FEV1/FVC, FVC, TLC, DLCO are expressed as percentage of 3 
predicted value. 4 
 5 
Figure 2. Lung Function Score (LuFS) before allo-SCT, 100 days, 1 year and 2 years after 6 
allo-SCT. A separate score was assigned to relative values of FEV1 and DLCO (>80% = 1, 7 
70-79% = 2, 60-69% = 3, 50-59% = 4, 40-49%=5, <40%=6), these scores were then summed 8 
and divided into four categories: LuFS 2 = category 0, LuFS 3-5 = category 1, LuFS 6-9 = 9 
category 2, LuFS 10-12 = category 3. No patient had severely abnormal lung function. There 10 
were no statistical differences in changes of LuFS before and after allo-SCT (Before allo-SCT 11 
vs 100 days (p=0.53), vs 1 year (p=0.29), vs 2 years (p=0.54)). 12 
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Table 1. Demographic characteristics of patients and transplant-related events 1 
Characteristic (%) Study population 
(N=52) 
Patient age, median (range) 
 
59 (23-70) 
Patient gender 
Male 
Female 
 
 
32 (62) 
20 (38) 
Smoker 
Yes 
No 
Data missing 
 
 
23 (44%) 
21 (40%) 
8 (15%) 
CMV serologic status 
Seronegative donor-recipient pair 
 
 
23 (44%) 
 
Diagnosis 
AML 
MDS 
NHL 
Other* 
 
 
22 (42) 
10 (19) 
13 (25) 
7 (14) 
 
Stem cell source 
Bone marrow  
PBSC 
 
 
2 (4) 
50 (96) 
Donor type 
Matched related donor (MRD) 
Unrelated donor (UD) 
 
 
29 
23 
 
CD34+ cell infused, × 106/Kg, median (range) 
 
6.22 (1.15-16.3) 
 
GVHD prophylaxis  
CsA alone 
CsA + MMF 
 
 
31 (60) 
21 (40) 
 
Grade 3-4 aGVHD at day 100 (cumulative 
incidence) 
 
15.4% 
Extensive cGVHD at 2 years (cumulative 
incidence) 
 
23.1% 
Abbreviations : CMV indicates cytomegalovirus; AML acute myelogenous leukemia; MDS myelodysplastic 2 
syndrome; NHL, non-Hodgkin lymphoma; CsA, Ciclosporine A; MMF, mycophenolate mofetil. 3 
*Others: 3 Hodgkin’s disease, 3 multiple myeloma and 1 acute lymphoblastic leukemia. 4 
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Table 2. PFT Data Obtained Pretransplantation and at 100 Days, 1 Year, and 2 Years 1 
Posttransplantation (Median expressed as percentage of predicted value). 2 
 3 
 
FEV1, 
Median 
[range] 
FVC, 
Median 
[range] 
FEV1/FVC, 
Median 
[range] 
TLC, 
Median  
[range] 
DLCO, 
Median 
[range] 
Pretransplantation (n = 52) 
 
109.8 
[68.5- 137.3] 
108.2 
 [66.5-138.4] 
80.9  
[55.3-98.1] 
104.5  
[65.2-137.1] 
69  
[37.5-96.1] 
Day 100 (n = 40) 
 
105.1  
[71.5-135.1]  
105.8  
[68.1-136.3] 
78.48  
[55.5-91.1] 
105.8  
[77.9-138.7] 
69.8 
[43.3-106.3] 
1 year (n = 32) 
 
103.4 
 [56.1-143.7]  
106.7  
[59-139] 
76.86 
[62.8-89.9] 
103.7 
[76.2-132.2] 
70 
[37.4-94.4] 
2 years (n = 28) 
 
100.6  
[63.8-118.1] 
102.7  
[63.9-117.8] 
76.2  
[58.7-90.7] 
104.4 
[79-144.9] 
68.1  
[34.4-86.2] 
Abbreviations: FEV1 indicates forced expiratory volume in 1 second; FVC, forced vital capacity; 4 
TLC, total lung capacity; DLCO, lung carbon monoxide diffusing capacity. 5 
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